Technical Data
LRP, MVP (Major Vault Protein, Lung-resistance Related Protein)
Flow Cytometry (cell permeabilization required)
Immunocytochemistry (cytospin preparations)
Immunohistochemistry (frozen sections, paraffin sections)
Recommended starting dilution is 1:20. Optimal conditions must be determined individually for each application.
25ug-20CBlue IceHumanRat
Human MVP/LRP (major vault protein/lung resistance protein).
Liquid. Antibody in serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide.
Recognizes an internal epitope of human MVP/LRP, which is strongly overexpressed in various human non-P-glycoprotein MDR tumor cell lines.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance: R.J. Scheper, et al.; Cancer Res. 53, 1475 (1993)
2. Membrane transport proteins associated with drug resistance expressed in human melanoma: D. Schadendorf, et al.; Am J. Pathol. 147, 1545 (1995)
3. The drug resistance-related protein LRP is the human major vault protein: G.L. Scheffer, et al.; Nature Med. 1, 578 (1995)
4. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification: M.L. Slovak, et al.; Cancer Res. 55, 4214 (1995)
5. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors: M.A. Izquierdo, et al.; Am. J. Pathol. 148, 877 (1996)
6. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia: A.F. List, et al.; Blood 87, 2464 (1996)
7. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia: M.L. Den Boer, et al.; Leukemia 11, 1078 (1997)
8. Identification of novel drug resistance-associated proteins by a panel of rat monoclonal antibodies: M.J. Flens, et al.; Int. J. Cancer 73, 249 (1997)
9. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP: U. Stein, et al.; J. Natl. Cancer Inst. 89, 807 (1997)
10. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival: A.G. Borg, et al.; Br. J. Haematol. 103, 1083 (1998)
11. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia: M.L. Den Boer, et al.; Blood 91, 2092 (1998)
12. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma: H.G. Raaijmakers, et al.; Blood 91, 1029 (1998)
13. Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues: A.B. Schroeijers, et al.; Am. J. Pathol. 152, 373 (1998)
14. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma: H.J. Arts, et al.; Clin. Cancer Res. 5, 2798 (1999)
15. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma: M. Filipits, et al.; Clin. Cancer Res. 5, 2426 (1999)
16. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis: G.A. Meijer, et al.; J. Clin. Pathol. 52, 450 (1999)
17. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines: V. Nuessler, et al.; Leukemia 13, 1864 (1999)
18. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts: M. Pallis, et al.; Adv. Exp. Med. Biol. 457, 77 (1999)
19. The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia: R. Pirker, et al.; Adv. Exp. Med. Biol. 457, 133 (1999)
20. Expression of the lung resistance protein (LRP) in primary breast cancer: G. Pohl, et al.; Anticancer Res. 19, 5051 (1999)
21. Multidrug resistance related proteins in primary cutaneous lymphomas: C.W. van Haselen, et al.; Adv. Exp. Med. Biol. 457, 119 (1999)
22. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells: G.K. Chen, et al.; Br. J. Cancer 83, 892 (2000)
23. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas: M. Filipits, et al.; Clin. Cancer Res. 6, 3417 (2000)
24. Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo: H. Kusakabe, et al.; Arch. Dermatol. Res. 292, 292 (2000)
25. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas: D. Mayr, et al.; Pathol. Res. Pract. 196, 469 (2000)
26. Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies: A.B. Schroeijers, et al.; J. Histochem. Cytochem. 49, 1379 (2001)